PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
October 10, 2025Discover Oncology3 citationsOpen Access

The global, regional, and national burden of acute lymphoblastic leukemia, 1990 to 2021: a cross-sectional analysis from the 2021 global burden of disease study

View Full Paper
YCYuan ChenAnhui UniversityMZMengqi ZhuShanghai Medical College of Fudan UniversityYSYi ShiHuzhou University

Key Points

  • In 2021, acute lymphoblastic leukemia caused 386,813 prevalent cases worldwide, representing a 10.3% increase since 1990.
  • Mortality rate for acute lymphoblastic leukemia significantly declined by 41.8%, with age-standardized prevalence rate rising from 4.1 to 5.4 per 100,000 individuals.
  • The study utilized data from the Global Burden of Disease Study 2021 and involved advanced analytical methods including Bayesian Age-Period-Cohort modeling.
  • Health inequalities widened in the past three decades, with significant disparities in both prevalence and mortality rates between high and low socio-demographic index regions.

Abstract

Acute lymphoblastic leukemia (ALL) remains a major public health challenge, yet its global burden and epidemiological trends are inadequately characterized. This study evaluates the global burden of ALL from 1990 to 2021 and projects trends through 2040. Using data from the Global Burden of Disease (GBD) Study 2021, we analyzed prevalence, incidence, mortality, disability-adjusted life years (DALYs), and age-standardized rates (ASRs) for ALL, stratified by time, region, age, and Socio-Demographic Index (SDI). Advanced methods included estimated annual percentage change (EAPC), Joinpoint regression, decomposition and frontier analyses, and Bayesian Age-Period-Cohort (BAPC) modeling to quantify trends, inequalities, and projections. In 2021, ALL caused 386,813 prevalent cases globally (10.3% increase since 1990) and 71,221 deaths (41.8% decline). Age-standardized prevalence rate (ASPR) rose from 4.1 to 5.4 per 100,000 (EAPC = 1.4), while mortality rate (ASMR) decreased significantly (EAPC = − 1.73). High SDI regions exhibited the highest ASPR (16.1 vs. 1.3 per 100,000 in low-SDI areas) but lower ASMR (0.5 vs. 1.3) and DALY rates (23.7 vs. 47.9). A bimodal age distribution peaked in children < 5 years (21.5 per 100,000), with male predominance across ages. Modifiable risks included high BMI (5.8% of global deaths) and smoking (15.4% in high-income North America). Health inequalities widened: the slope index of inequality for prevalence increased from 3.22 to 4.23 (1990–2021), and ASDR disparity reached − 30.97. Frontier analysis highlighted untapped ASDR reduction potential in low-SDI nations (97.17–136.34 per 100,000). Projections suggest a 50% global ASPR decline by 2040 (2.84 per 100,000), though regional disparities persist. The global ALL burden reflects progress and disparity: high-SDI regions face rising prevalence and aging-related challenges despite mortality declines, while low-SDI areas grapple with entrenched inequities. Age- and sx-specific patterns, alongside modifiable risks, necessitate targeted prevention and equity-driven policies.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68e9435d2d5336d28fb289c5https://doi.org/10.1007/s12672-025-03683-w
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990–2021: a systematic analysis for the Global Burden of Disease Study 20212024 · 4,897 citations
  2. 2Aging and cancer2024 · 181 citations
  3. 3Neighborhood and Individual Socioeconomic Disadvantage and Survival Among Patients With Nonmetastatic Common Cancers2021 · 180 citations
  4. 4Asprosin Exerts Pro-Inflammatory Effects in THP-1 Macrophages Mediated via the Toll-like Receptor 4 (TLR4) Pathway2022 · 36 citations
  5. 5Worldwide comparison of survival from childhood leukaemia for 1995–2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries2017 · 217 citations